Format

Send to

Choose Destination
Int J Mol Imaging. 2012;2012:175803. doi: 10.1155/2012/175803. Epub 2012 Aug 10.

The role of fluorine-18-fluorodeoxyglucose positron emission tomography in evaluating the response to treatment in patients with multiple myeloma.

Author information

1
Department of Bioimaging and Radiological Sciences, Institute of Nuclear Medicine, Università Cattolica del Sacro Cuore, Largo Gemelli 8, 00168 Rome, Italy.

Abstract

BACKGROUND AND AIM:

Fluorine-18-fluorodeoxyglucose positron emission tomography (FDG-PET) is well recognized as a powerful diagnostic tool in the initial staging of patients with multiple myeloma (MM). The aim of this paper is to perform a systematic review about the usefulness of FDG-PET or PET/CT in evaluating the response to treatment in patients with MM.

METHODS:

The scientific literature about the role of FDG-PET or PET/CT in evaluating the response to treatment in patients affected by MM was systematically reviewed.

RESULTS:

Ten studies about the role of FDG-PET or PET/CT in evaluating treatment response in MM were retrieved and discussed.

CONCLUSIONS:

FDG-PET or PET/CT seems to be helpful in assessing the response to treatment in patients with MM and in the evaluation of possible sites of recurrent or progressive disease.

Supplemental Content

Full text links

Icon for Hindawi Limited Icon for PubMed Central
Loading ...
Support Center